ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia

Patent Enables Equivalent Efficacy with 10 times Lower Energy Consumption Than Current Device

Read more at globenewswire.com